MSGM Clinical Case Discussion October 2026

The Gravity Trap: The Hidden Autonomic Collapse in Parkinson’s

Prepared by Dr Kwa Schee Li

Supervised by: Dr. Tunku Muzafar Shah, Dr. Nurul Huda binti Mohd Zambri

Case Summary

Mr. FCT is a 71-year-old man with Hoehn and Yahr Stage 4 Parkinson’s disease (diagnosed in 2019) and a Clinical Frailty Scale (CFS) score of 6. His comorbidities include type 2 diabetes mellitus, hypertension, ischemic heart disease, dyslipidemia, benign prostatic hyperplasia (BPH), and paroxysmal atrial fibrillation. He has resided in a nursing home since 2023 due to functional decline.

Previously able to ambulate short distances using a walking frame with assistance, he experienced a progressive decline in mobility with recurrent falls since early 2026. He also reports severe postural giddiness upon standing. He requires assistance with bathing, dressing and toileting in the nursing home.

He was initially admitted for an acute gastroenteritis from the ED. The diagnosis was revised to chronic constipation with overflow diarrhoea after a comprehensive assessment. His inpatient hospital stay was complicated by acute urinary retention, recurrent E. coli catheterassociated urinary tract infection (CAUTI) and bacteraemia, a sacral sore and persistent delirium.

He was also noted to have fragmented nocturnal sleep, frequent daytime naps and sleep-related behaviours such as talking during sleep and reaching for non-existent objects which complicated the management.

The following were his medications prior to admission :

• T. Madopar 125 mg QID since January 2023

• T. Madopar HBS 250 mg ON since April 2026.

• T. Clonazepam 0.5 mg ON (August 2025) for suspected REM sleep behaviour disorder/sleep disturbance.

• T. Rivaroxaban 20mg OD

• T. Metformin 500mg BD

• T. Cardiprin 100mg OD

• T. Atorvastatin 20mg ON

• T. Perindopril 4mg OD

• T. Alfuzosin 10mg ON

On further assessment, it became apparent that the patient had not been taking the Madopar HBS as prescribed. He reduced it to 125 mg ON as he reported feeling weaker following the dose increase. He also discontinued the clonazepam after two weeks due to reported confusion.

Physical and Cognitive Examination

Neurological Examination:

90 Examination revealed a mask-like facies, lead- pipe rigidity and bradykinesia. There was no obvious tremor or cerebellar signs. Postural BP testing revealed significant giddiness upon sitting with syncope upon standing. He regained consciousness spontaneously after returning to the supine position on bed.

Cognitive and Mood:

His Mini-Mental State Examination (MMSE) score was 21/30 (orientation 6/10, attention 3/5, recall 0) .

His Geriatric Depression Scale (GDS) was 5/15.

Blood investigation 24/8/26

Renal Profile : Na 135 K 4.0 Urea 7.6 Creatinine 139.

Full Blood Count : Hb 10 WCC 7.4 Platelet 236

Thyroid Function 30/6/26: T4 16.5 TSH 0.41

Serum cortisol 8am 30/6/26 : 531

HBA1C 25/6/26 : 6.7%

ECHO 24/7/26:

EF 45-50%,

Hypokinetic motion appear at basal anterior, basal anteroseptal

LA Dilated with area 21.7cm², volume 62ml

RA RV not dilated

LV hypertrophy (IVSd 1.4cm)

Aorta/ PA 1:1

Mild MR, Trivial AR, Mild TR with TR

There was a delay in rehabilitation due to the acute medical issue and delirium. Postural BP and tilt table testing was done once stable. The finding are shown in the Table above. Despite a profound fall in blood pressure, there was no compensatory increase in heart rate.

Clinical Questions Part 1 :

1. What are the key clinical issues and non-motor complications affecting this patient with long-standing advanced Parkinson’s disease?

2. How should his overall medication regimen be adjusted to balance dopaminergic requirements against severe orthostatic hypotension and polypharmacy risks?

3. What evidence-based interventions (pharmacological and non-pharmacological) can address his orthostatic hypotension, sleep disturbances, and constipation?

4. Suggest a management strategy for his BPH and urinary retention, given that alphablockers exacerbates his postural hypotension? 5. Is concurrent Rivaroxaban and Aspirin (Cardiprin) therapy clinically indicated? What is the optimal strategy for his Atrial Fibrillation and underlying IHD?

Clinical Progress

Both pharmacological and non-pharmacological interventions were implemented following a comprehensive medication reconciliation as below:

• Off T. Perindopril 4mg OD

• Off T. Alfuzosin 10mg ON

• Off T. Rivaroxaban 20mg OD in view of very high fall risk and moderate frailty

• T. Cardiprin 100mg OD

• Change T. Madopar HBS 125mg BD

• ↓T. Madopar 62.5mg OM

• + Syrup Lactulose 15 ml TDS

• + T. bisacodyl 10mg OD

Non-pharmacologically, TED stocking and an abdominal binder was applied prior to sitting or transferring. He demonstrated remarkable functional improvement: able to tolerate sitting upright for up to 1 hour without giddiness, despite hypotension. In contrast, removing the binder resulted in syncope within 5 minutes of upright positioning. The following tables summarises the blood pressure, heart rate and associated symptoms observed during tilt-table training and sitting in a chair.

Fludrocortisone was started 3/7/26 – 28/7/26

Midodrine was started 29/7/26 till now

* Midodrine TDS was administered at 8:00 AM, 12:00 PM, and 4:00 PM, patient was propped up at a 45-degree angle for 4 hours following each dose of midodrine, with the final daily dose administered before late afternoon to prevent supine hypertension

Given his severe neurogenic orthostatic hypotension (nOH) and recurrent acute urinary retention (AUR) secondary to severe BPH, a long-term catheterization strategy was adopted. This decision eliminates the need for alpha-blockers, avoiding iatrogenic exacerbation of his postural hypotension, preventing recurrent urinary retention, bladder-distension-induced dysautonomia, and secondary delirium.

Clinical Questions Part 2

1. How should we navigate the therapeutic trade-off between neurogenic orthostatic hypotension (nOH) and nocturnal supine hypertension in this patient?

2. What pharmacological options are available for postural hypotension, including their recommended starting doses, dose titration, and monitoring parameters?

3. What specific physical therapy and tilt-table habituation schedules are evidence-based for transitioning severe nOH patients from seated stability to safe standing/transfers?

References:

1) Newton, J. L., & Frith, J. (2018). The efficacy of nonpharmacologic intervention for orthostatic hypotension associated with aging. Neurology, 91(7), e652–e656.

2) Figueroa, J. J., Basford, J. R., & Low, P. A. (2010). Preventing and treating orthostatic hypotension: As easy as A, B, C. Cleveland Clinic journal of medicine, 77(5), 298–306.

3) Verheyden, B., Ector, H., Aubert, A. E., & Reybrouck, T. (2008). Tilt training increases the vasoconstrictor reserve in patients with neurally mediated syncope evoked by headup tilt testing. European heart journal, 29(12), 1523–1530.

4) Hornikx M, Haemers P, Stans L, Robyns T, Garweg C, Ector J, Vandenberk B and Willems R (2024) Tilt training as a treatment for reflex syncope: a multimodal approach!?. Front. Neurosci. 18:1473687.

5) Turner, L. N., & Gorelick, P. B. (2025, September 14). Diagnosis and management of orthostatic hypotension in individuals with Parkinson disease. Practical Neurology (US)

6) Rissardo, J.P., Gadelmawla, A.F., Khalil, I., Abdulgadir, A., Bhatti, K.S., & Fornari Caprara, A.L. (2025). Epidemiology of autonomic dysfunction in Parkinson's disease (Review). Medicine International, 5, 68

7) Cattaneo, C., Fabbrini, A., Belvisi, D., Aiello, F., Marchet, F., & Fabbrini, G. (2026). Non-Motor Symptoms: The Hidden Face of Parkinson’s Disease. Cells, 15(1), 42

8) Seppi, K., et al. (2019). Update on treatments for nonmotor symptoms of Parkinson's disease: An evidence-based medicine review. Movement Disorders, 34(2), 180–198.